Circulating tumor eccDNA in ovarian cancer reflects Chemotherapy response and survival

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200059226

Enrollment

Unknown

Registered

2022-04-27

Start date

2021-01-01

Completion date

Unknown

Last updated

2024-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

Gold Standard:Pathological diagnosis

Index test:eccDNA

Eligibility

Sex/Gender

Female

Age

30 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.The experimental group was ovarian cancer patients with pathological diagnosis of ovarian malignancy, and did not receive any treatment; 2.The control group was healthy people.

Exclusion criteria

Exclusion criteria: 1. Ovarian cancer patients who have received radiotherapy and chemotherapy; 2. Ovarian metastatic tumor from other organ tumors; 3. Patients with a history of rheumatic immune disease.

Design outcomes

Primary

Measure	Time frame
eccDNA;	—

Countries

China

Contacts

Public ContactWang Jing

The fist affiliated hospital of Anhui Medical university

sabrinawangjing@163.com+86 13956068241

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026